Published in:
01-01-2019 | HEAD, NECK AND DENTAL RADIOLOGY
Cervical lymphadenopathy: can the histogram analysis of apparent diffusion coefficient help to differentiate between lymphoma and squamous cell carcinoma in patients with unknown clinical primary tumor?
Authors:
Antonello Vidiri, Silvia Minosse, Francesca Piludu, Raul Pellini, Giovanni Cristalli, Ramy Kayal, Giorgio Carlino, Daniela Renzi, Renato Covello, Simona Marzi
Published in:
La radiologia medica
|
Issue 1/2019
Login to get access
Abstract
Purpose
To retrospectively evaluate the value of whole-lesion histogram analysis of apparent diffusion coefficient (ADC) maps in differentiating between lymphoma and metastatic squamous cell carcinoma (SCC) of unknown clinical primary in neck nodes.
Methods
A total of 39 patients, 20 affected by lymphoma and 19 affected by metastatic non-nasopharyngeal SCC, were included in this retrospective study. All patients underwent MR imaging with a 1.5 T scanner system, including diffusion-weighted imaging (DWI) with three different b values (b = 0, 500 and 800 s/mm2). The entire tumor volume was manually delineated on the ADC maps, using the T2-weighted images and DWIs with b = 800 s/mm2 as a guide to the lesion location. The Mann–Whitney rank-sum test for independent samples was performed to compare the histogram parameters of patients with lymphoma and SCC.
Results
The SCCs showed significantly higher median ADC (ADCmedian) and mean ADC (ADCmean) values, compared to lymphomas (p < 0.001), while they exhibited lower kurtosis and skewness without reaching significance (p = 0.066 and 0.148, respectively). The ADCmean and ADCmedian had the best discriminative powers for differentiating lymphoma and SCC, with an area under the curve of 87% and 85%, respectively. The optimal cutoff values for ADCmean and ADCmedian as predictors for lymphoma were ≤ 0.83 × 10−3 mm2/s and ≤ 0.73 × 10−3 mm2/s, respectively.
Conclusions
The whole-lesion ADC histogram analysis of cervical lymphadenopathy may help to discriminate lymphomas from non-nasopharyngeal SCC in patients with unknown clinical primary tumor.